173 related articles for article (PubMed ID: 30117318)
1. Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).
Ustun C; Morgan E; Moodie EEM; Pullarkat S; Yeung C; Broesby-Olsen S; Ohgami R; Kim Y; Sperr W; Vestergaard H; Chen D; Kluin PM; Dolan M; Mrózek K; Czuchlewski D; Horny HP; George TI; Kristensen TK; Ku NK; Yi CA; Møller MB; Marcucci G; Baughn L; Schiefer AI; Hilberink JR; Pullarkat V; Shanley R; Kohlschmidt J; Coulombe J; Salhotra A; Soma L; Cho C; Linden MA; Akin C; Gotlib J; Hoermann G; Hornick J; Nakamura R; Deeg J; Bloomfield CD; Weisdorf D; Litzow MR; Valent P; Huls G; Perales MA; Borthakur G
Cancer Med; 2018 Sep; 7(9):4447-4455. PubMed ID: 30117318
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes.
Kuwatsuka Y; Miyamura K; Suzuki R; Kasai M; Maruta A; Ogawa H; Tanosaki R; Takahashi S; Koda K; Yago K; Atsuta Y; Yoshida T; Sakamaki H; Kodera Y
Blood; 2009 Feb; 113(9):2096-103. PubMed ID: 19126873
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
[TBL] [Abstract][Full Text] [Related]
4. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
5. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
[TBL] [Abstract][Full Text] [Related]
6. [Heterogeneity of acute myeloid leukemia with the translocation t(8;21)(q22;q22)].
Gritsaev SV; Martynkevich IS; Ziuzgin IS; Kariagina EV; Martynenko LS; Petrova EV; Tsybakova NIu; Ivanova MP; Kostroma II; Tiranova SA; Potikhonova NA; Abdulkadyrov KM
Ter Arkh; 2014; 86(7):45-52. PubMed ID: 25314777
[TBL] [Abstract][Full Text] [Related]
7. Core binding factor acute myeloid leukemia.
Paschka P
Semin Oncol; 2008 Aug; 35(4):410-7. PubMed ID: 18692691
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.
Cairoli R; Beghini A; Grillo G; Nadali G; Elice F; Ripamonti CB; Colapietro P; Nichelatti M; Pezzetti L; Lunghi M; Cuneo A; Viola A; Ferrara F; Lazzarino M; Rodeghiero F; Pizzolo G; Larizza L; Morra E
Blood; 2006 May; 107(9):3463-8. PubMed ID: 16384925
[TBL] [Abstract][Full Text] [Related]
9. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
Prébet T; Boissel N; Reutenauer S; Thomas X; Delaunay J; Cahn JY; Pigneux A; Quesnel B; Witz F; Thépot S; Ugo V; Terre C; Recher C; Tavernier E; Hunault M; Esterni B; Castaigne S; Guilhot F; Dombret H; Vey N; ; ;
J Clin Oncol; 2009 Oct; 27(28):4747-53. PubMed ID: 19720919
[TBL] [Abstract][Full Text] [Related]
11. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.
Mosna F; Papayannidis C; Martinelli G; Di Bona E; Bonalumi A; Tecchio C; Candoni A; Capelli D; Piccin A; Forghieri F; Bigazzi C; Visani G; Zambello R; Zanatta L; Volpato F; Paolini S; Testoni N; Gherlinzoni F; Gottardi M
Am J Hematol; 2015 Jun; 90(6):515-23. PubMed ID: 25753065
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and prognostic factors of acute myeloid leukemia with t (8; 21) (q22; q22).
Lai YY; Qiu JY; Jiang B; Lu XJ; Huang XJ; Zhang Y; Liu YR; Shi HL; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):733-40. PubMed ID: 16277833
[TBL] [Abstract][Full Text] [Related]
13. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
14. [A multivariate model for predicting induction response and prognosis in core binding factor acute myeloid leukemia].
Wang B; Hua XY; Lin RR; Yang B; Wu W; He B; Zhang XW; Xing SS; Li HQ
Zhonghua Nei Ke Za Zhi; 2019 Nov; 58(11):796-802. PubMed ID: 31665853
[No Abstract] [Full Text] [Related]
15. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
[TBL] [Abstract][Full Text] [Related]
16. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ
J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and prognostic factors analysis of core binding factor acute myeloid leukemia in real world.
Zhai Y; Wang Q; Ji L; Ren H; Dong Y; Yang F; Yin Y; Liang Z; Wang Q; Liu W; Mei Y; Zhang L; Li Y
Cancer Med; 2023 Dec; 12(24):21592-21604. PubMed ID: 38062912
[TBL] [Abstract][Full Text] [Related]
18. [Clinical analysis of acute myeloid leukemia with t(8;21) (q22;q22) and loss of Y chromosome].
Zhu CY; Yang H; Niu JH; Zhang Q; Xie XL; Wang LJ; Zhu HY; Yao ZL; Yu L; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):950-6. PubMed ID: 25130809
[TBL] [Abstract][Full Text] [Related]
19. Prognosis and treatment outcome in patients with acute myeloid leukemia with t(8;21)(q22;q22).
Chen CC; Gau JP; Yu YB; Lu CH; Lee KD; You JY
Adv Ther; 2007; 24(4):907-20. PubMed ID: 17901040
[TBL] [Abstract][Full Text] [Related]
20. Different prognostic effects of core-binding factor positive AML with Korean AML registry data.
Shin HJ; Min WS; Min YH; Cheong JW; Lee JH; Kim IH; Hong DS; Ahn JS; Kim HJ; Lee WS; Jung CW; Jang JH; Park Y; Kim HJ;
Ann Hematol; 2019 May; 98(5):1135-1147. PubMed ID: 30758645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
